Drug Trial Radar · NCT07714447
Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
91
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Feb 1, 2029
Study completion Feb 26, 2029
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigated the efficacy and safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer.
Conditions
- CRC (Colorectal Cancer)
- BRAF
Interventions
Arm1Drug
Tunlametinib + Cetuximab β Injection
Arm 2Drug
Tunlametinib + Cetuximab β+Tislelizumab
Arm 3Drug
Tunlametinib + BRAF inhibitor + Tislelizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: up to 180 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.